New pill could stop dangerous swelling attacks in hereditary angioedema patients

NCT ID NCT05396105

ENROLLING_BY_INVITATION Disease control Sponsor: Pharvaris Netherlands B.V. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 23 times

Summary

This study tests an oral medication called deucrictibant for quickly treating sudden swelling attacks in people with hereditary angioedema (HAE), including life-threatening throat swelling. About 150 adults who have completed earlier studies or are new to the drug will take the pill at the start of an attack. The goal is to see if it is safe and effective for long-term, on-demand use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Study site

Birmingham, Alabama, 35209, United States
Study site

Scottsdale, Arizona, 85258, United States
Study site

Little Rock, Arkansas, 72205, United States
Study site

San Diego, California, 92122, United States
Study site

Santa Monica, California, 90404, United States
Study site

Walnut Creek, California, 94598, United States
Study site

Colorado Springs, Colorado, 80907, United States
Study site

Chevy Chase, Maryland, 20815, United States
Study site

Boston, Massachusetts, 02115, United States
Study site

Detroit, Michigan, 48202, United States
Study site

St Louis, Missouri, 63141, United States
Study site

Hershey, Pennsylvania, 17033, United States
Study site

Dallas, Texas, 75231, United States
Study site

Buenos Aires, B1629AHJ, Argentina
Study site

Salta, 4400, Argentina
Study site

Campbelltown, New South Wales, 2560, Australia
Study site

Graz, 8036, Austria
Study site

Vienna, 1090, Austria
Study site

Salvador, Estado de Bahia, 41950-640, Brazil
Study site

Ribeirão Preto, 14048-900, Brazil
Study site

Santo André, 09060-870, Brazil
Study site

São Paulo, 05403-000, Brazil
Study site

Sofia, 1431, Bulgaria
Study site

Sofia, 1680, Bulgaria
Study site

Edmonton, Alberta, T6G 1Z1, Canada
Study site

Montreal, Quebec, Canada
Study site

Brno, 602 00, Czechia
Study site

Grenoble, 38043, France
Study site

Paris, 75571, France
Study site

Berlin, 12203, Germany
Study site

Frankfurt am Main, 60590, Germany
Study site

Frankfurt am Main, 60596, Germany
Study site

Lübeck, 23538, Germany
Study site

Hong Kong, Hong Kong
Study site

Budapest, 1088, Hungary
Study site

Ashkelon, 78278, Israel
Study site

Catania, 95124, Italy
Study site

Milan, 20097, Italy
Study site

Milan, 20138, Italy
Study site

Naples, 80131, Italy
Study site

Padova, 35128, Italy
Study site

Palermo, 90146, Italy
Study site

Roma, 00133, Italy
Study site

Hiroshima, 730-8518, Japan
Study site

Kanagawa, 216-8511, Japan
Study site

Osaka, 569-8686, Japan
Study site

Tokyo, 113-8431, Japan
Study site

Tokyo, 133-8431, Japan
Study site

Amsterdam, 1005 AZ, Netherlands
Study site

Krakow, 31-503, Poland
Study site

San Juan, 918, Puerto Rico
Study site

San Juan, 927, Puerto Rico
Study site

Riyadh, 11471, Saudi Arabia
Study site

Cape Town, 7700, South Africa
Study site

Daegu, 41944, South Korea
Study site

Seoul, 03080, South Korea
Study site

Barcelona, 08035, Spain
Study site

Barcelona, 08907, Spain
Study site

Madrid, 28007, Spain
Study site

Lund, 22185, Sweden
Study site

Ankara, 06230, Turkey (Türkiye)
Study site

Istanbul, 34093, Turkey (Türkiye)
Study site

London, E1 2ES, United Kingdom

Conditions

Explore the condition pages connected to this study.